secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2026-08-21T21:00:20+00:00
Accession:  0001104659-26-099731
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia completes SimpliDerm sale to Cellution for $11M; adds $7.7M net cash
---------------------------------------------------------------------------

- Closed Aug 17, 2026 sale of Women's Health hADM assets to Cellution Biologics.
- Received $7.7M net cash ($8M at close less inventory adjustments); up to $3M contingent milestones over 18 months.
- Transaction treated as discontinued operations; estimated pre-tax gain of $4.9M.
- Pro forma H1 2026 continuing ops net loss $16.2M ($0.37/share) vs $15.5M reported.
- NXT-41x (antibiotic-eluting biomatrix) FDA clearance expected H1 2027; funding secured through launch year 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926099731/0001104659-26-099731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465926099731/elut-20260817x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-099731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer